Table 2:

Adverse events reported during study participation. (Neuro = neurologic, Malig. = malignancy, AML = acute myelogenous leukemia, MDS = myelodysplastic syndrome)

	Regimen 1			Regimen 2			Regimen 3
Adverse Events	A11G	G3/4	G5	A11G	G3/4	G5	A11G	G3/4	G5
Hematologic
Anemia	95%	25%	0	99%	47%	0	92%	26%	0
Neutropenia	98%	92%	0	94%	83%	0	91%	74%	0
Febrile Neutropenia	13%	13%	0	4%	4%	0	4%	4%	0
Thrombocytopenia	91%	33%	0	59%	27%	0	63%	15%	0
Gastrointestinal
Abdominal Pain	43%	5%	0	54%	6%	0	66%	7%	0
Perforation (Colon)	1%	1%	0	0	0	0	3%	3%	0
Perforation (SI)	1%	1%	0	1%	1%	0	0	0	0
Constipation	66%	2%	0	62%	1%	0	68%	1%	0
Diarrhea	45%	1%	0	59%	6%	0	57%	6%	0
Dyspepsia	15%	1%	0	13%	0	0	14%	0	0
Mucositis	28%	0	0	30%	0	0	34%	2%	0
Nausea	84%	6%	0	77%	6%	0	90%	12%	0
Vomiting	40%	4%	0	38%	6%	0	59%	10%	0
Cardiovascular
Thrombo-embolic	10%	5%	1%	13%	5%	0	19%	9%	0
Stroke	1%	0	0	0	0	0	2%	1%	0
Hypertension	55%	27%	0	58%	30%	0	64%	29%	0
Epistaxis	29%	1%	0	47%	1%	0	24%	0	0
Vaginal Bleeding	5%	0	0	8%	0	0	2%	1%	0
General/Neuro									0
Anorexia	43%	1%	0	42%	3%	0	59%	1%	0
Fatigue	89%	5%	0	90%	6%	0	88%	9%	0
Headache	39%	1%	0	52%	2%	0	50%	1%	0
Insomnia	29%	0	0	33%	1%	0	23%	0	0
Myalgia	36%	0	0	29%	1%	0	27%	0	0
Sensory Neuropathy	67%	0	0	65%	2%	0	61%	0	0
Motor Neuropathy	8%	1%	0	6%	0	0	4%	0	0
Renal
Creatinine elevation	14%	0	0	13%	0	0	27%	1%	0
Proteinuria	12%	3%	0	9%	3%	0	14%	2%	0
Respiratory
Dyspnea	39%	0	0	45%	5%	0	35%	2%	0
Secondary Malig.
AML	1%	1%	0	0	0	0	0	0	0
MDS	1%	1%	0	0	0	0	0	0	0
Infections/Infestation
Lung infection	1.8%	1.2%	0%	4.7%	3.1%	.8%	2.4%	1.6%	0
Sepsis	1.8%	1.2%	.6%	3.1%	2.3%	.8%	4.0%	2.4%	1.6%
Psychiatric
Suicide (attempt)	0.6%	0.6%	0	0	0	0	.8%	0	.8%